drugset / Trial / NCT07590167

A Study to Evaluate the Safety and Pharmacokinetics of AD-231 Compared to Coadministration of AD-231A, AD-231D and AD-231C

NCT07590167 ↗

Phase 1 Not yet recruiting 60 enrolled Addpharma Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

A Study to Evaluate the Safety and Pharmacokinetics of AD-231 Compared to Coadministration of AD-231A, AD-231D and AD-231C

Timeline

Start
2026-06
Primary completion
2026-07
Completion
2026-07

Drugs

EvaluationDrugModalityDoseRoute
Subject AD-231 Unknown — Oral
Subject AD-231A Unknown — Oral
Subject AD-231C Unknown — Oral
Subject AD-231D Unknown — Oral